Scleroderma lung disease

Clinical Reviews in Allergy and Immunology

Volumn 40, Issue 2, 2011, Pages 104-116

  Le Pavec, Jérôme ^a,b   Launay, David ^c   Mathai, Stephen C ^b   Hassoun, Paul M ^b   Humbert, Marc ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b Harry and Jeannette Weinberg Cancer Center   (United States)

^c UNIV LILLE   (France)

Author keywords

Interstitial lung disease; Pulmonary arterial hypertension; Scleroderma; Scleroderma lung disease; Scleroderma related pulmonary arterial hypertension

Indexed keywords

AZATHIOPRINE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMATINIB; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE; PROSTACYCLIN; SILDENAFIL;

ARTICLE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LOW DRUG DOSE; LUNG ASPIRATION; LUNG CANCER; LUNG DISEASE; LUNG FIBROSIS; LUNG TRANSPLANTATION; NEUROMUSCULAR DISEASE; PLEURA EFFUSION; PNEUMOTHORAX; PREVALENCE; PROGNOSIS; PULMONARY HYPERTENSION; SCLERODERMA; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; PREVALENCE; PROGNOSIS; RESPIRATORY ASPIRATION; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 79951681966     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12016-009-8194-2     Document Type: Article

References (152)

1. SA Jimenez CT Derk 2004 Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis Ann Intern Med 140 37 50 1:CAS:528:DC%2BD2cXotVWmtA%3D%3D 14706971 (Pubitemid 38055920)
2. FK Tan 2003 Systemic sclerosis: the susceptible host (genetics and environment) Rheum Dis Clin North Am 29 211 237 12841292 (Pubitemid 36765118)
3. EC LeRoy C Black R Fleischmajer S Jablonska T Krieg TA Medsger Jr N Rowell F Wollheim 1988 Scleroderma (systemic sclerosis): classification, subsets and pathogenesis J Rheumatol 15 202 205 1:STN:280:DyaL1c3gtVWnsg%3D%3D 3361530 (Pubitemid 18073738)
4. RM Silver 1996 Scleroderma. Clinical problems. The lungs Rheum Dis Clin North Am 22 825 840 1:STN:280:DyaK2s%2Fot1emtA%3D%3D 8923598
5. VD Steen TA Medsger 2007 Changes in causes of death in systemic sclerosis, 1972-2002 Ann Rheum Dis 66 940 944 17329309 (Pubitemid 46999798)
6. E Diot E Boissinot E Asquier JL Guilmot E Lemarie C Valat P Diot 1998 Relationship between abnormalities on high-resolution ct and pulmonary function in systemic sclerosis Chest 114 1623 1629 1:STN:280:DyaK1M%2FoslajsQ%3D%3D 9872198 (Pubitemid 128487485)
7. AU Wells MB Rubens RM du Bois DM Hansell 1993 Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern AJR Am J Roentgenol 161 1159 1165 1:STN:280:DyaK2c%2FntVGhsw%3D%3D 8249719 (Pubitemid 24008055)
8. P Ostojic N Damjanov 2006 Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis Clin Rheumatol 25 453 457 16261285 (Pubitemid 44137613)
9. SP Toya GE Tzelepis 2009 The many faces of scleroderma sine scleroderma: a literature review focusing on cardiopulmonary complications Rheumatol Int 29 861 868 19247661
10. S Morelli C Barbieri A Sgreccia L Ferrante V Pittoni F Conti G Gualdi E Polettini OA Carlesimo S Calvieri 1997 Relationship between cutaneous and pulmonary involvement in systemic sclerosis J Rheumatol 24 81 85 1:STN:280:DyaK2s7lsFejsw%3D%3D 9002015 (Pubitemid 27059862)
11. TA McNearney JD Reveille M Fischbach AW Friedman JR Lisse N Goel FK Tan X Zhou C Ahn CA Feghali-Bostwick, et al. 2007 Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors Arthritis Rheum 57 318 326 17330281 (Pubitemid 47164096)
12. GC Kane J Varga EF Conant PW Spirn S Jimenez JE Fish 1996 Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status Respir Med 90 223 230 1:STN:280:DyaK283pslGhtQ%3D%3D 8736656 (Pubitemid 26130211)
13. Alton E (1988) Turner-Warwick M. Lung involvement in scleroderma. Black, CM, Jayson MIV, Wiley, Chichester
14. EL Greidinger KT Flaherty B White A Rosen FM Wigley RA Wise 1998 African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease Chest 114 801 807 1:CAS:528:DyaK1cXmsVClsLg%3D 9743170 (Pubitemid 28433744)
15. Y Okano VD Steen TA Medsger Jr 1992 Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis Arthritis Rheum 35 95 100 1:STN:280:DyaK387hvVWntg%3D%3D 1731817
16. DG Sacks Y Okano VD Steen E Curtiss LS Shapiro TA Medsger Jr 1996 Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3rnp antibody J Rheumatol 23 639 642 1:STN:280:DyaK283otVWlsg%3D%3D 8730118 (Pubitemid 26139635)
17. VD Steen 2005 Autoantibodies in systemic sclerosis Semin Arthritis Rheum 35 35 42 1:CAS:528:DC%2BD2MXntVOisL0%3D 16084222 (Pubitemid 41111469)
18. VD Steen DL Powell TA Medsger Jr 1988 Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis Arthritis Rheum 31 196 203 1:STN:280:DyaL1c7mt12nsQ%3D%3D 3348823 (Pubitemid 18088039)
19. DJ Wallace HC Lin GQ Shen JB Peter 1994 Antibodies to histone (h2a-h2b)-DNA complexes in the absence of antibodies to double-stranded DNA or to (h2a-h2b) complexes are more sensitive and specific for scleroderma-related disorders than for lupus Arthritis Rheum 37 1795 1797 1:CAS:528: DyaK2MXjtV2hsrs%3D 7986226
20. A Fischer JJ Swigris SD Groshong CD Cool H Sahin DA Lynch D Curran-Everett JZ Gillis RT Meehan KK Brown 2008 Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival Chest 134 601 605 18403656
21. AU Wells DM Hansell MB Rubens AD King D Cramer CM Black RM du Bois 1997 Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography Arthritis Rheum 40 1229 1236 1:STN:280:DyaK2szlslSksw%3D%3D 9214422 (Pubitemid 27430133)
22. D Bouros AU Wells AG Nicholson TV Colby V Polychronopoulos P Pantelidis PL Haslam DA Vassilakis CM Black RM du Bois 2002 Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome Am J Respir Crit Care Med 165 1581 1586 12070056 (Pubitemid 34693935)
23. Kim EA, Lee KS, Johkoh T, Kim TS, Suh GY, Kwon OJ, Han J (2002) Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics 22 Spec No:S151-S165 (Pubitemid 41569704)
24. D Launay M Remy-Jardin U Michon-Pasturel I Mastora E Hachulla M Lambert V Delannoy V Queyrel A Duhamel R Matran, et al. 2006 High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis J Rheumatol 33 1789 1801 16960939 (Pubitemid 44373213)
25. JG Goldin DA Lynch DC Strollo RD Suh DE Schraufnagel PJ Clements RM Elashoff DE Furst S Vasunilashorn MF McNitt-Gray, et al. 2008 High-resolution ct scan findings in patients with symptomatic scleroderma-related interstitial lung disease Chest 134 358 367 18641099
26. NS Goh SR Desai S Veeraraghavan DM Hansell SJ Copley TM Maher TJ Corte CR Sander J Ratoff A Devaraj, et al. 2008 Interstitial lung disease in systemic sclerosis: a simple staging system Am J Respir Crit Care Med 177 1248 1254 18369202 (Pubitemid 351860934)
27. J Fujita T Yoshinouchi Y Ohtsuki M Tokuda Y Yang I Yamadori S Bandoh T Ishida J Takahara R Ueda 2001 Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis Ann Rheum Dis 60 281 283 1:STN:280: DC%2BD3M7lvVagug%3D%3D 11171693 (Pubitemid 32260614)
28. Y Nakamura K Chida T Suda H Hayakawa M Iwata S Imokawa T Tsuchiya M Ida H Gemma K Yasuda, et al. 2003 Nonspecific interstitial pneumonia in collagen vascular diseases: comparison of the clinical characteristics and prognostic significance with usual interstitial pneumonia Sarcoidosis Vasc Diffuse Lung Dis 20 235 241 14620168 (Pubitemid 37351546)
29. D Tansey AU Wells TV Colby S Ip A Nikolakoupolou RM du Bois DM Hansell AG Nicholson 2004 Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis Histopathology 44 585 596 1:STN:280:DC%2BD2c3os12itA%3D%3D 15186274 (Pubitemid 38845105)
30. MR al-Sabbagh VD Steen BC Zee M Nalesnik DC Trostle CD Bedetti TA Medsger Jr 1989 Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study J Rheumatol 16 1038 1042 1:STN:280: DyaK3c%2FmsVehtA%3D%3D 2585400 (Pubitemid 19234729)
31. AU Wells DM Hansell MB Rubens P Cullinan CM Black RM du Bois 1993 The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis Am Rev Respir Dis 148 1076 1082 1:STN:280:DyaK2c%2FivVejug%3D%3D 8214928 (Pubitemid 23301234)
32. NL Muller RR Miller 1990 Computed tomography of chronic diffuse infiltrative lung disease. Part 1 Am Rev Respir Dis 142 1206 1215 1:STN:280:DyaK3M%2Flt1Ohug%3D%3D 2240845 (Pubitemid 20384388)
33. AU Wells DM Hansell MB Rubens P Cullinan PL Haslam CM Black RM Du Bois 1994 Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings relation to computed tomographic appearance Am J Respir Crit Care Med 150 462 468 1:STN:280:DyaK2czis1Smsg%3D%3D 8049830 (Pubitemid 24252359)
34. NK Harrison AR Glanville B Strickland PL Haslam B Corrin BJ Addis R Lawrence AB Millar CM Black M Turner-Warwick 1989 Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mtc-dtpa clearance Respir Med 83 403 414 1:STN:280:DyaK3c7jvFOjsg%3D%3D 2694236 (Pubitemid 19247077)
35. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups 1990 The BAL cooperative group steering committee Am Rev Respir Dis 141 S169 S202
36. DP Tashkin R Elashoff PJ Clements J Goldin MD Roth DE Furst E Arriola R Silver C Strange M Bolster, et al. 2006 Cyclophosphamide versus placebo in scleroderma lung disease N Engl J Med 354 2655 2666 1:CAS:528: DC%2BD28XmtFSgtLs%3D 16790698
37. Al-Dhaher FF, Pope JE, Ouimet JM (2008) Determinants of morbidity and mortality of systemic sclerosis in canada. Semin Arthritis Rheum
38. RD Altman TA Medsger Jr DA Bloch BA Michel 1991 Predictors of survival in systemic sclerosis (scleroderma) Arthritis Rheum 34 403 413 1:STN:280:DyaK3M7ptVWlsg%3D%3D 1901491
39. KB Highland RM Silver 2005 New developments in scleroderma interstitial lung disease Curr Opin Rheumatol 17 737 745 16224252 (Pubitemid 41546493)
40. VD Steen GR Owens TA Medsger Jr 1994 Severe restrictive lung disease in systemic sclerosis Arthritis Rheum 37 1283 1289 1:STN:280:DyaK2M%2Fjt1aguw%3D%3D 7945490 (Pubitemid 24320744)
41. VD Steen TA Medsger Jr 2000 Severe organ involvement in systemic sclerosis with diffuse scleroderma Arthritis Rheum 43 2437 2444 1:STN:280:DC%2BD3M%2FktFequw%3D%3D 11083266
42. C Strange MB Bolster MD Roth RM Silver A Theodore J Goldin P Clements J Chung RM Elashoff R Suh, et al. 2008 Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease Am J Respir Crit Care Med 177 91 98 1:CAS:528:DC%2BD1cXht12mt7k%3D 17901414
43. A Akesson A Scheja A Lundin FA Wollheim 1994 Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide Arthritis Rheum 37 729 735 1:STN:280:DyaK2c3kt1WhtQ%3D%3D 8185701 (Pubitemid 24145078)
44. B White WC Moore FM Wigley HQ Xiao RA Wise 2000 Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis Ann Intern Med 132 947 954 1:CAS:528: DC%2BD3cXkslylsb8%3D 10858177 (Pubitemid 30397594)
45. P Airo E Danieli G Parrinello CM Antonioli I Cavazzana P Toniati F Franceschini R Cattaneo 2004 Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results Clin Exp Rheumatol 22 573 578 1:STN:280:DC%2BD2crhsVOmtg%3D%3D 15485010 (Pubitemid 39302934)
46. B Griffiths S Miles H Moss R Robertson D Veale P Emery 2002 Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function J Rheumatol 29 2371 2378 1:CAS:528:DC%2BD38XptVGgt7s%3D 12415594 (Pubitemid 35266028)
47. I Pakas JP Ioannidis K Malagari FN Skopouli HM Moutsopoulos PG Vlachoyiannopoulos 2002 Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease J Rheumatol 29 298 304 1:CAS:528: DC%2BD38XhsF2iu78%3D 11842824 (Pubitemid 34118777)
48. RM Silver JH Warrick MB Kinsella LS Staudt MH Baumann C Strange 1993 Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease J Rheumatol 20 838 844 1:STN:280:DyaK3szivFKktA%3D%3D 8336309 (Pubitemid 23158478)
49. VD Steen JK Lanz Jr C Conte GR Owens TA Medsger Jr 1994 Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study Arthritis Rheum 37 1290 1296 1:STN:280:DyaK2M%2Fjt1ansg%3D%3D 7945491 (Pubitemid 24320745)
50. S Apras I Ertenli Z Ozbalkan S Kiraz MA Ozturk IC Haznedaroglu V Cobankara S Pay M Calguneri 2003 Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis Arthritis Rheum 48 2256 2261 1:CAS:528:DC%2BD3sXntVWgsbk%3D 12905480 (Pubitemid 36959207)
51. EM Davas C Peppas M Maragou E Alvanou D Hondros PC Dantis 1999 Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma Clin Rheumatol 18 455 461 1:STN:280: DC%2BD3c7gt1ejug%3D%3D 10638770 (Pubitemid 30014164)
52. FJ Martinez WJ McCune 2006 Cyclophosphamide for scleroderma lung disease N Engl J Med 354 2707 2709 1:CAS:528:DC%2BD28XmtFSgsb0%3D 16790705
53. DP Tashkin R Elashoff PJ Clements MD Roth DE Furst RM Silver J Goldin E Arriola C Strange MB Bolster, et al. 2007 Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease Am J Respir Crit Care Med 176 1026 1034 1:CAS:528:DC%2BD2sXhsVekt7%2FN 17717203 (Pubitemid 350127847)
54. RK Hoyles RW Ellis J Wellsbury B Lees P Newlands NS Goh C Roberts S Desai AL Herrick NJ McHugh, et al. 2006 A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma Arthritis Rheum 54 3962 3970 1:CAS:528: DC%2BD2sXktlalug%3D%3D 17133610 (Pubitemid 44955900)
55. C Nannini CP West PJ Erwin EL Matteson 2008 Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies Arthritis Res Ther 10 R124 18937831
56. A Berezne B Ranque D Valeyre M Brauner Y Allanore D Launay V Le Guern JE Kahn LJ Couderc J Constans, et al. 2008 Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study J Rheumatol 35 1064 1072 1:CAS:528: DC%2BD1cXotlWmsL4%3D 18464307 (Pubitemid 351813153)
57. O Nadashkevich P Davis M Fritzler W Kovalenko 2006 A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis Clin Rheumatol 25 205 212 1:STN:280:DC%2BD283ivFOjug%3D%3D 16228107 (Pubitemid 43372319)
58. RJ Stratton H Wilson CM Black 2001 Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma Rheumatology (Oxford) 40 84 88 1:CAS:528:DC%2BD3MXhtlKhtLk%3D
59. SN Liossis A Bounas AP Andonopoulos 2006 Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease Rheumatology (Oxford) 45 1005 1008 1:CAS:528:DC%2BD28Xotl2ku7w%3D (Pubitemid 44283057)
60. JJ Swigris AL Olson A Fischer DA Lynch GP Cosgrove SK Frankel RT Meehan KK Brown 2006 Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease Chest 130 30 36 1:CAS:528:DC%2BD28Xot1KjtL8%3D 16840379 (Pubitemid 44116838)
61. AC Zamora PJ Wolters HR Collard MK Connolly BM Elicker WR Webb TE King Jr JA Golden 2008 Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease Respir Med 102 150 155 17822892 (Pubitemid 350151821)
62. AJ Gerbino CH Goss JA Molitor 2008 Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease Chest 133 455 460 1:CAS:528:DC%2BD1cXjtFemsLg%3D 18071023 (Pubitemid 351272405)
63. MC Vonk Z Marjanovic FH van den Hoogen S Zohar AV Schattenberg WE Fibbe J Larghero E Gluckman FW Preijers AP van Dijk, et al. 2008 Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis Ann Rheum Dis 67 98 104 1:STN:280:DC%2BD2sjjslKnug%3D%3D 17526554
64. JC Bonner 2004 Regulation of PDGF and its receptors in fibrotic diseases Cytokine Growth Factor Rev 15 255 273 1:CAS:528:DC%2BD2cXltVKhtL8%3D 15207816 (Pubitemid 38781050)
65. J Rosenbloom SA Jimenez 2008 Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis Arthritis Rheum 58 2219 2224 1:CAS:528:DC%2BD1cXhtVCjtbbP 18668575
66. V Rosas JV Conte SC Yang SP Gaine M Borja FM Wigley B White JB Orens 2000 Lung transplantation and systemic sclerosis Ann Transplant 5 38 43 1:STN:280:DC%2BD3M7ksFelsg%3D%3D 11147028
67. MG Massad CR Powell J Kpodonu C Tshibaka Z Hanhan NJ Snow AS Geha 2005 Outcomes of lung transplantation in patients with scleroderma World J Surg 29 1510 1515 16222454 (Pubitemid 41712692)
68. LJ Rubin 1997 Primary pulmonary hypertension N Engl J Med 336 111 117 1:STN:280:DyaK2s7jtVSlug%3D%3D 8988890 (Pubitemid 27020889)
69. B Chang FM Wigley B White RA Wise 2003 Scleroderma patients with combined pulmonary hypertension and interstitial lung disease J Rheumatol 30 2398 2405 14677184 (Pubitemid 37413900)
70. AJ MacGregor R Canavan C Knight CP Denton J Davar J Coghlan CM Black 2001 Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival Rheumatology (Oxford) 40 453 459 1:STN:280: DC%2BD3M3it1KktA%3D%3D
71. I Murata K Takenaka S Yoshinoya K Kikuchi T Kiuchi T Tanigawa K Ito 1997 Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients Chest 111 36 43 1:STN:280:DyaK2s7kvFWrsA%3D%3D 8995990 (Pubitemid 27043604)
72. FM Wigley JA Lima M Mayes D McLain JL Chapin C Ward-Able 2005 The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the uncover study) Arthritis Rheum 52 2125 2132 15986394 (Pubitemid 40994336)
73. JE Pope P Lee M Baron J Dunne D Smith PS Docherty A Bookman M Abu-Hakima 2005 Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis J Rheumatol 32 1273 1278 15996064 (Pubitemid 40995382)
74. E Hachulla V Gressin L Guillevin P Carpentier E Diot J Sibilia A Kahan J Cabane C Frances D Launay, et al. 2005 Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study Arthritis Rheum 52 3792 3800 16320330 (Pubitemid 41798217)
75. D Mukerjee D St George B Coleiro C Knight CP Denton J Davar CM Black JG Coghlan 2003 Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach Ann Rheum Dis 62 1088 1093 1:STN:280:DC%2BD3srgslKquw%3D%3D 14583573 (Pubitemid 37323574)
76. M Humbert O Sitbon A Chaouat M Bertocchi G Habib V Gressin A Yaici E Weitzenblum JF Cordier F Chabot, et al. 2006 Pulmonary arterial hypertension in france: results from a national registry Am J Respir Crit Care Med 173 1023 1030 16456139
77. E Hachulla P de Groote V Gressin J Sibilia E Diot P Carpentier L Mouthon PY Hatron P Jego Y Allanore, et al. 2009 The 3-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France (itinérair-sclérodermie study) Arthritis Rheum 60 1831 1839 19479881
78. V Steen TA Medsger Jr 2003 Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement Arthritis Rheum 48 516 522 12571862 (Pubitemid 36278021)
79. V Steen 2003 Predictors of end stage lung disease in systemic sclerosis Ann Rheum Dis 62 97 99 1:STN:280:DC%2BD3s%2FhvVOiug%3D%3D 12525376 (Pubitemid 36135382)
80. B Chang L Schachna B White FM Wigley RA Wise 2006 Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma J Rheumatol 33 269 274 16465657 (Pubitemid 43209302)
81. SR Cox JG Walker M Coleman M Rischmueller S Proudman MD Smith MJ Ahern PJ Roberts-Thomson 2005 Isolated pulmonary hypertension in scleroderma Intern Med J 35 28 33 1:STN:280:DC%2BD2M%2FktVGhuw%3D%3D 15667465 (Pubitemid 40254764)
82. E Hachulla JG Coghlan 2004 A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism Ann Rheum Dis 63 1009 1014 1:CAS:528:DC%2BD2cXnvFWksbk%3D 15308510 (Pubitemid 39120347)
83. R Scorza M Caronni S Bazzi F Nador L Beretta R Antonioli L Origgi A Ponti M Marchini M Vanoli 2002 Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis Ann N Y Acad Sci 966 238 246 12114278 (Pubitemid 34729180)
84. SC Plastiras SP Karadimitrakis C Kampolis HM Moutsopoulos GE Tzelepis 2007 Determinants of pulmonary arterial hypertension in scleroderma Semin Arthritis Rheum 36 392 396 17204309 (Pubitemid 46776817)
85. YY Ong T Nikoloutsopoulos CP Bond MD Smith MJ Ahern PJ Roberts-Thomson 1998 Decreased nailfold capillary density in limited scleroderma with pulmonary hypertension Asian Pac J Allergy Immunol 16 81 86 1:STN:280: DyaK1M%2Fpt1OksA%3D%3D 9876945 (Pubitemid 29004827)
86. CY Lee SM Chang SH Hsiao JC Tseng SK Lin CP Liu 2007 Right heart function and scleroderma: insights from tricuspid annular plane systolic excursion Echocardiography 24 118 125 17313542
87. SH Hsiao CY Lee SM Chang SK Lin CP Liu 2006 Right heart function in scleroderma: insights from myocardial Doppler tissue imaging J Am Soc Echocardiogr 19 507 514 16644433
88. C Meune J Avouac K Wahbi L Cabanes J Wipff L Mouthon L Guillevin A Kahan Y Allanore 2008 Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: a controlled study of 100 consecutive patients Arthritis Rheum 58 1803 1809 18512815 (Pubitemid 351847535)
89. MH Williams CE Handler R Akram CJ Smith C Das J Smee D Nair CP Denton CM Black JG Coghlan 2006 Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension Eur Heart J 27 1485 1494 1:CAS:528:DC%2BD28Xnt1Giu7o%3D 16682379 (Pubitemid 43998084)
90. MH Williams C Das CE Handler MR Akram J Davar CP Denton CJ Smith CM Black JG Coghlan 2006 Systemic sclerosis associated pulmonary hypertension: improved survival in the current era Heart 92 926 932 1:STN:280:DC%2BD28zmtVKmsw%3D%3D 16339813 (Pubitemid 43974055)
91. ET Koh P Lee DD Gladman M Abu-Shakra 1996 Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients Br J Rheumatol 35 989 993 1:STN:280:DyaK2s%2Fjslyisg%3D%3D 8883438
92. MD Mayes 2003 Scleroderma epidemiology Rheum Dis Clin North Am 29 239 254 12841293 (Pubitemid 36765119)
93. MR Fisher SC Mathai HC Champion RE Girgis T Housten-Harris L Hummers JA Krishnan F Wigley PM Hassoun 2006 Clinical differences between idiopathic and scleroderma-related pulmonary hypertension Arthritis Rheum 54 3043 3050 16947776 (Pubitemid 44497786)
94. RE Girgis SC Mathai JA Krishnan FM Wigley PM Hassoun 2005 Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases J Heart Lung Transplant 24 1626 1631 16210140 (Pubitemid 41396463)
95. SM Kawut DB Taichman CL Archer-Chicko HI Palevsky SE Kimmel 2003 Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis Chest 123 344 350 12576350 (Pubitemid 36269414)
96. KP Kuhn DW Byrne PG Arbogast TP Doyle JE Loyd IM Robbins 2003 Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol Am J Respir Crit Care Med 167 580 586 12446266
97. R Condliffe DG Kiely AJ Peacock PA Corris JS Gibbs F Vrapi C Das CA Elliot M Johnson J DeSoyza, et al. 2009 Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era Am J Respir Crit Care Med 179 151 157 18931333
98. E Hachulla P Carpentier V Gressin E Diot Y Allanore J Sibilia D Launay L Mouthon P Jego J Cabane, et al. 2009 Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French itinérair- sclérodermie study Rheumatology (Oxford) 48 304 308
99. PR Forfia MR Fisher SC Mathai T Housten-Harris AR Hemnes BA Borlaug E Chamera MC Corretti HC Champion TP Abraham, et al. 2006 Tricuspid annular displacement predicts survival in pulmonary hypertension Am J Respir Crit Care Med 174 1034 1041 16888289 (Pubitemid 44684453)
100. PR Forfia SC Mathai MR Fisher T Housten-Harris AR Hemnes HC Champion RE Girgis PM Hassoun 2008 Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension Am J Respir Crit Care Med 177 1364 1369 1:CAS:528:DC%2BD1cXot1Wgtbw%3D 18356560 (Pubitemid 351860914)
101. GE D'Alonzo RJ Barst SM Ayres EH Bergofsky BH Brundage KM Detre AP Fishman RM Goldring BM Groves JT Kernis, et al. 1991 Survival in patients with primary pulmonary hypertension. Results from a national prospective study Ann Intern Med 115 343 349 1863023
102. R Budhiraja RM Tuder PM Hassoun 2004 Endothelial dysfunction in pulmonary hypertension Circulation 109 159 165 14734504 (Pubitemid 38114133)
103. O Sitbon M Humbert X Jais V Ioos AM Hamid S Provencher G Garcia F Parent P Herve G Simonneau 2005 Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension Circulation 111 3105 3111 1:CAS:528:DC%2BD2MXkvVCmu74%3D 15939821 (Pubitemid 40847788)
104. P Dorfmuller F Perros K Balabanian M Humbert 2003 Inflammation in pulmonary arterial hypertension Eur Respir J 22 358 363 1:STN:280: DC%2BD3svht1yntw%3D%3D 12952274 (Pubitemid 36987011)
105. O Sanchez O Sitbon X Jais G Simonneau M Humbert 2006 Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension Chest 130 182 189 1:CAS:528:DC%2BD28Xot1KjtLg%3D 16840400 (Pubitemid 44116858)
106. X Jais D Launay A Yaici J Le Pavec C Tcherakian O Sitbon G Simonneau M Humbert 2008 Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases Arthritis Rheum 58 521 531 18240255 (Pubitemid 351294886)
107. JR Vane EE Anggard RM Botting 1990 Regulatory functions of the vascular endothelium N Engl J Med 323 27 36 1:CAS:528:DyaK3cXls1Gntrc%3D 2113184 (Pubitemid 20209469)
108. RJ Barst LJ Rubin WA Long MD McGoon S Rich DB Badesch BM Groves VF Tapson RC Bourge BH Brundage, et al. 1996 A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group N Engl J Med 334 296 302 1:CAS:528:DyaK28XhsVShs70%3D 8532025
109. VV McLaughlin DE Genthner MM Panella S Rich 1998 Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension N Engl J Med 338 273 277 1:CAS:528: DyaK1cXpslaktA%3D%3D 9445406 (Pubitemid 28065252)
110. LJ Rubin J Mendoza M Hood M McGoon R Barst WB Williams JH Diehl J Crow W Long 1990 Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial Ann Intern Med 112 485 491 1:STN:280:DyaK3c7ps1Omsw%3D%3D 2107780 (Pubitemid 20100285)
111. VV McLaughlin A Shillington S Rich 2002 Survival in primary pulmonary hypertension: the impact of epoprostenol therapy Circulation 106 1477 1482 1:CAS:528:DC%2BD38XntVKksb0%3D 12234951
112. O Sitbon M Humbert H Nunes F Parent G Garcia P Herve M Rainisio G Simonneau 2002 Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival J Am Coll Cardiol 40 780 788 1:CAS:528:DC%2BD38XntVKjsr0%3D 12204511 (Pubitemid 34925627)
113. DB Badesch VF Tapson MD McGoon BH Brundage LJ Rubin FM Wigley S Rich RJ Barst PS Barrett KM Kral, et al. 2000 Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial Ann Intern Med 132 425 434 1:CAS:528:DC%2BD3cXit1SmsL8%3D 10733441 (Pubitemid 30149039)
114. HW Farber KK Graven G Kokolski JH Korn 1999 Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma J Rheumatol 26 1195 1196 1:STN:280:DyaK1M3mtlOrtw%3D%3D 10332990 (Pubitemid 29215090)
115. SM Palmer LJ Robinson A Wang JR Gossage T Bashore VF Tapson 1998 Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease Chest 113 237 240 1:STN:280: DyaK1c7gtFGntQ%3D%3D 9440597 (Pubitemid 28044953)
116. P Dorfmuller M Humbert F Perros O Sanchez G Simonneau KM Muller F Capron 2007 Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases Hum Pathol 38 893 902 17376507 (Pubitemid 46735956)
117. LJ Rubin DB Badesch RJ Barst N Galie CM Black A Keogh T Pulido A Frost S Roux I Leconte, et al. 2002 Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 896 903 1:CAS:528:DC%2BD38Xit1ekur0%3D 11907289 (Pubitemid 34984638)
118. RN Channick G Simonneau O Sitbon IM Robbins A Frost VF Tapson DB Badesch S Roux M Rainisio F Bodin, et al. 2001 Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study Lancet 358 1119 1123 1:CAS:528:DC%2BD3MXntlOrurs%3D 11597664 (Pubitemid 32971843)
119. Hachulla AL, Launay D, Gaxotte V, de Groote P, Lamblin N, Devos P, Hatron PY, Beregi JP, Hachulla E (2008) Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis
120. CP Denton M Humbert L Rubin CM Black 2006 Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions Ann Rheum Dis 65 1336 1340 1:CAS:528:DC%2BD28Xht1egsLbF 16793845 (Pubitemid 44620443)
121. DB Badesch NS Hill G Burgess LJ Rubin RJ Barst N Galie G Simonneau 2007 Sildenafil for pulmonary arterial hypertension associated with connective tissue disease J Rheumatol 34 2417 2422 17985403 (Pubitemid 350230665)
122. G Simonneau LJ Rubin N Galie RJ Barst TR Fleming AE Frost PJ Engel MR Kramer G Burgess L Collings, et al. 2008 Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial Ann Intern Med 149 521 530 18936500
123. SC Mathai RE Girgis MR Fisher HC Champion T Housten-Harris A Zaiman PM Hassoun 2007 Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension Eur Respir J 29 469 475 1:CAS:528:DC%2BD2sXjs1yksLk%3D 17079256 (Pubitemid 46372092)
124. L Schachna FM Wigley B Chang B White RA Wise AC Gelber 2003 Age and risk of pulmonary arterial hypertension in scleroderma Chest 124 2098 2104 14665486 (Pubitemid 38010575)
125. SC Mathai L Hummers HC Champion F Wigley A Zaiman PM Hassoun R Girgis 2009 Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease Arthritis Rheum 60 569 577 19180517
126. DA Johnson WE Drane J Curran EL Cattau Jr C Ciarleglio A Khan J Cotelingam SB Benjamin 1989 Pulmonary disease in progressive systemic sclerosis. A complication of gastroesophageal reflux and occult aspiration? Arch Intern Med 149 589 593 1:STN:280:DyaL1M7kvFaltA%3D%3D 2919934 (Pubitemid 19092856)
127. I Marie S Dominique H Levesque P Ducrotte P Denis MF Hellot H Courtois 2001 Esophageal involvement and pulmonary manifestations in systemic sclerosis Arthritis Rheum 45 346 354 1:STN:280:DC%2BD3Mvls1ChtA%3D%3D 11501722 (Pubitemid 32738740)
128. G Lock M Pfeifer RH Straub M Zeuner B Lang J Scholmerich A Holstege 1998 Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis Am J Gastroenterol 93 341 345 1:STN:280:DyaK1c7ns1yisQ%3D%3D 9517636 (Pubitemid 29068333)
129. AJ Ing 2001 Interstitial lung disease and gastroesophageal reflux Am J Med 111 Suppl 8A 41S 44S 11749923 (Pubitemid 34031990)
130. MB Troshinsky GC Kane J Varga JR Cater JE Fish SA Jimenez DO Castell 1994 Pulmonary function and gastroesophageal reflux in systemic sclerosis Ann Intern Med 121 6 10 1:STN:280:DyaK2c3ls1OgsQ%3D%3D 8198350
131. CE Daniels JR Jett 2005 Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med 11 431 437 16093818 (Pubitemid 41291088)
132. B Hazleman 1985 Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens Am J Med 78 39 43 1:STN:280:DyaL2M7hvFartw%3D%3D 3970039 (Pubitemid 15167364)
133. CL Hill AM Nguyen D Roder P Roberts-Thomson 2003 Risk of cancer in patients with scleroderma: a population based cohort study Ann Rheum Dis 62 728 731 1:STN:280:DC%2BD3szlsVSqtg%3D%3D 12860727 (Pubitemid 36886406)
134. AK Rosenthal JK McLaughlin MS Linet I Persson 1993 Scleroderma and malignancy: an epidemiological study Ann Rheum Dis 52 531 533 1:STN:280:DyaK3szkvFWgtw%3D%3D 8346981 (Pubitemid 23227219)
135. Y Yang J Fujita M Tokuda S Bandoh T Ishida 2001 Lung cancer associated with several connective tissue diseases: with a review of literature Rheumatol Int 21 106 111 1:STN:280:DC%2BD38%2FjvVeitg%3D%3D 11765223 (Pubitemid 33071192)
136. AD Roumm TA Medsger Jr 1985 Cancer and systemic sclerosis. An epidemiologic study Arthritis Rheum 28 1336 1340 1:STN:280:DyaL287gtlCruw%3D%3D 4084328 (Pubitemid 16156143)
137. S Chatterjee GW Dombi RK Severson MD Mayes 2005 Risk of malignancy in scleroderma: a population-based cohort study Arthritis Rheum 52 2415 2424 16052585 (Pubitemid 41117427)
138. KB Highland MC Garin KK Brown 2007 The spectrum of scleroderma lung disease Semin Respir Crit Care Med 28 418 429 17764059 (Pubitemid 350194724)
139. PJ Clements DE Furst DS Campion A Bohan R Harris J Levy HE Paulus 1978 Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations Arthritis Rheum 21 62 71 1:STN:280:DyaE1c7gtlegtA%3D%3D 623695 (Pubitemid 9127954)
140. NJ Olsen LE King Jr JH Park 1996 Muscle abnormalities in scleroderma Rheum Dis Clin North Am 22 783 796 1:STN:280:DyaK2s%2Fot1emtg%3D%3D 8923596 (Pubitemid 26396051)
141. MJ Abramson AJ Barnett GO Littlejohn MM Smith S Hall 1991 Lung function abnormalities and decline of spirometry in scleroderma: an overrated danger? Postgrad Med J 67 632 637 1:STN:280:DyaK38%2FitVGhtQ%3D%3D 1924047
142. C Vitali G Viegi S Tassoni A Tavoni P Paoletti E Bibolotti C Ferri S Bombardieri 1986 Lung function abnormalities in different connective tissue diseases Clin Rheumatol 5 181 188 1:STN:280:DyaL283ntlSktQ%3D%3D 3731715
143. B Blom-Bulow B Jonson K Brauer 1985 Lung function in progressive systemic sclerosis is dominated by poorly compliant lungs and stiff airways Eur J Respir Dis 66 1 8 1:STN:280:DyaL2M7lsVeqsA%3D%3D 3979473 (Pubitemid 15192902)
144. GR Owens GJ Fino DL Herbert VD Steen TA Medsger Jr BE Pennock JJ Cottrell GP Rodnan RM Rogers 1983 Pulmonary function in progressive systemic sclerosis. Comparison of crest syndrome variant with diffuse scleroderma Chest 84 546 550 1:STN:280:DyaL2c%2Fislymuw%3D%3D 6628005 (Pubitemid 14228964)
145. RD Bjerke DP Tashkin PJ Clements SK Chopra H Gong Jr M Bein 1979 Small airways in progressive systemic sclerosis (PSS) Am J Med 66 201 209 1:STN:280:DyaE1M7kt1Cntw%3D%3D 425965 (Pubitemid 9119040)
146. A Boehler P Vogt R Speich W Weder EW Russi 1996 Bronchiolitis obliterans in a patient with localized scleroderma treated with d-penicillamine Eur Respir J 9 1317 1319 1:STN:280:DyaK28zpvVSksg%3D%3D 8804954 (Pubitemid 26231752)
147. AE Thompson JE Pope 1998 A study of the frequency of pericardial and pleural effusions in scleroderma Br J Rheumatol 37 1320 1323 1:STN:280:DyaK1M7jslCnsA%3D%3D 9973157
148. VJ Taormina WT Miller WB Gefter DM Epstein 1981 Progressive systemic sclerosis subgroups: variable pulmonary features AJR Am J Roentgenol 137 277 285 1:STN:280:DyaL3M3lt1Gqug%3D%3D 6789634
149. M Zeuner U Muller-Ladner VD Mohr B Lang 1996 Spontaneous pneumothorax in a patient with systemic sclerosis Clin Rheumatol 15 211 213 1:STN:280: DyaK283mtFymtA%3D%3D 8777861 (Pubitemid 26122583)
150. K Suresh R Radha G Ananthasubramaniam AN Chandrasekaran 1994 An unusual presentation of progressive systemic sclerosis J Assoc Physicians India 42 163 164 1:STN:280:DyaK2M7msVeqtw%3D%3D 7860485
151. SC Ng WC Tan 1990 Bilateral spontaneous pneumothorax in systemic sclerosis-report of two cases J Rheumatol 17 689 691 1:STN:280: DyaK3c3psVagsQ%3D%3D 2193158 (Pubitemid 20201751)
152. B Lang H Ortlieb S Meske G Hauke HH Peter 1989 Progressive systemic sclerosis presenting with spontaneous pneumothorax J Rheumatol 16 254 256 1:STN:280:DyaL1MzhtFaqtQ%3D%3D 2746577